VERTEPORFIN THERAPY OF SUBFOVEAL CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION: Meta-Analysis of 2-Year Safety Results in Three Randomized Clinical Trials: Treatment of Age-Related Macular Degeneration with Photodynamic Therapy and Verteporfin in Photodynamic Therapy Study Report

[1]  D. Devine,et al.  Liposome-complement interactions in rat serum: implications for liposome survival studies. , 1994, Biochimica et biophysica acta.

[2]  R. Spaide,et al.  Neutrophil margination as a possible mechanism for verteporfin infusion-associated pain. , 2003, American journal of ophthalmology.

[3]  Neil M Bressler,et al.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. , 2002, American journal of ophthalmology.

[4]  D. Devine,et al.  The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. , 1991, Journal of immunology.

[5]  J. Pohl,et al.  Low back pain associated with streptokinase , 1992, The Lancet.

[6]  J. Ruysschaert,et al.  Intravenous infusion of high doses of liposomes containing NSC 251635, a water-insoluble cytostatic agent. A pilot study with pharmacokinetic data. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  C. Alving,et al.  Complement activation by liposome-encapsulated hemoglobin in vitro: the role of endotoxin contamination. , 1995, Artificial cells, blood substitutes, and immobilization biotechnology.

[8]  U. G. Dailey.  Cancer,Facts and Figures about. , 2022, Journal of the National Medical Association.

[9]  T. Lint,et al.  Activation of human complement by liposomes: a model for membrane activation of the alternative pathway. , 1979, Journal of immunology.

[10]  M Shah,et al.  Low back pain associated with streptokinase. , 1990, BMJ.

[11]  J. Houle,et al.  DURATION OF SKIN PHOTOSENSITIVITY AND INCIDENCE OF PHOTOSENSITIVITY REACTIONS AFTER ADMINISTRATION OF VERTEPORFIN , 2002, Retina.

[12]  W. Amoaku,et al.  Treatment of Age-Related Macular Degeneration , 2004, Journal of the Royal Society of Medicine.

[13]  Simon P. Harding,et al.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2. , 2001, American journal of ophthalmology.

[14]  A. Skubitz,et al.  Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil™) , 1998, Anti-cancer drugs.

[15]  S. Winawer,et al.  Natural history of colorectal cancer. , 1999, The American journal of medicine.

[16]  A. Strong,et al.  Clinical Pharmacokinetics of Verteporfin , 2002, Journal of clinical pharmacology.

[17]  J. Jonas,et al.  Ophthalmoscopic measurement of the optic disc. , 1995, Ophthalmology.

[18]  J. Slakter,et al.  Verteporfin infusion-associated pain. , 2002, American journal of ophthalmology.

[19]  J. Cortes,et al.  Chest and Back Pain Associated with a Six-Hour Infusion of Liposomal Daunorubicin , 2000, The Annals of pharmacotherapy.

[20]  J. Jonas,et al.  Optic disc, cup and neuroretinal rim size, configuration and correlations in normal eyes. , 1988, Investigative ophthalmology & visual science.